AnHorn Medicines is a novel drug discovery company with a strong pipeline, offering therapies that target and degrade disease-causing proteins. Their mission is to develop new class of BIGPRO® (Bi-functional liGand induced PROteolysis) drugs under the foundation of Targeted Protein Degradation (TPD), to address a broad range of life-threatening and life-impairing diseases.